|
|
Company News
All Releases
 |
Achillion Reports Third Quarter 2008 Financial Results
Oct 28, 2008
|
13.9 KB |
|
| |
NEW HAVEN, Conn., Oct 28, 2008 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter and nine months ended September 30, 2008.
For the nine mon...
|
|
Data From Achillion's Antibacterial and HIV Programs Presented At the 2008 ICAAC/IDSA Joint Meeting
Oct 27, 2008
|
15.0 KB |
|
| |
Oct 27, 2008 (GlobeNewswire via COMTEX News Network) --
Four Posters Highlight Unique Mechanism and Broad-Spectrum
Antibacterial Activity of ACH-702
Unique Elvucitabine Activity Profile and 48-Week Phase 2 Results
Featured in Oral Presentation
NEW HAVEN, Conn., Oct. 27, 2008 (GLOBE ...
|
|
Achillion Appoints Nicholas Simon to Board of Directors
Aug 20, 2008
|
10.5 KB |
|
| |
NEW HAVEN, Conn., Aug 20, 2008 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the appointment of Nicholas Simon to its Board of Directors. Mr. Simon, who is Managing Directo...
|
|
Achillion Reports Second Quarter 2008 Financial Results
Aug 12, 2008
|
15.6 KB |
|
| |
NEW HAVEN, Conn., Aug 12, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter and six months ended June 30, 2008.
For the six months end...
|
|
Achillion to Present At Canaccord Adams Global Growth Conference
Aug 12, 2008
|
8.9 KB |
|
| |
NEW HAVEN, Conn., Aug 12, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, announced that Michael D. Kishbauch, President and Chief Executive Officer of Achillion, will be presenting a c...
|
|
Achillion Announces Private Placement Financing for up to $41.5 Million
Aug 6, 2008
|
13.2 KB |
|
| |
, Aug 6, 2008 (PrimeNewswire via COMTEX News Network) -- Proceeds to Fund Expanding Pipeline of Infectious Disease Candidates - - Company to Hold Conference Call to Discuss Second Quarter Results August 12 -
NEW HAVEN, Conn., Aug. 6, 2008 (PRIME NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and developmen...
|
|
Achillion Announces Additional Positive Top-Line Phase 2 Data for Elvucitabine
Jun 9, 2008
|
11.9 KB |
|
| |
NEW HAVEN, Conn., Jun 9, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced additional positive safety and efficacy results from its ongoing Phase 2 trial studying elvucita...
|
|
Achillion Nominates ACH-1625 as Lead Candidate in Proprietary Program Targeting HCV Protease
Jun 4, 2008
|
10.8 KB |
|
| |
NEW HAVEN, Conn., Jun 4, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the nomination of its first clinical candidate from the company's proprietary HCV protease program. The candidate, ACH-1625, is a highly selective inhibitor of HCV NS3 protease.
In preclinical studies, Achillion...
|
|
Achillion to Present At Needham Biotechnology Conference
May 23, 2008
|
8.9 KB |
|
| |
NEW HAVEN, Conn., May 23, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, announced that Michael D. Kishbauch, President and Chief Executive Officer of Achillion, will be presenting a c...
|
|
Achillion Reports First Quarter 2008 Financial Results
May 7, 2008
|
13.8 KB |
|
| |
NEW HAVEN, Conn., May 7, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter ended March 31, 2008.
For the first quarter of 2008, the Co...
|
|
Achillion and FOB Synthesis Announce Collaboration for the Development of Carbapenem Compounds
Apr 8, 2008
|
11.1 KB |
|
| |
NEW HAVEN, Conn. and KENNESAW, Ga., Apr 8, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) and FOB Synthesis, Inc. today announced that the companies have signed an exclusive agreement granting Achillion worldwide rights for the research, development and commercialization of certain FOB compounds for th...
|
|
Achillion Appoints Gary E. Frashier to Board of Directors
Apr 2, 2008
|
10.5 KB |
|
| |
NEW HAVEN, Conn., Apr 2, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc., (Nasdaq:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the appointment of Gary E. Frashier to its Board of Directors. Mr. Frashier, a principal with Ma...
|
|
Achillion to Present At Cowen Healthcare Conference
Mar 14, 2008
|
8.9 KB |
|
| |
NEW HAVEN, Conn., Mar 14, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, announced that Michael D. Kishbauch, President and Chief Executive Officer of Achillion, will be presenting a c...
|
|
Achillion Reports 2007 Fourth Quarter and Year-End Financial Results
Feb 27, 2008
|
16.6 KB |
|
| |
NEW HAVEN, Conn., Feb 27, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter and year ended December 31, 2007.
For the full year ended ...
|
|
Achillion to Present At the BIO CEO and Investor Conference
Feb 8, 2008
|
9.4 KB |
|
| |
NEW HAVEN, Conn., Feb 8, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion, will present a corporate overvi...
|
|
New Data for Achillion's Elvucitabine Demonstrate Drug's Safety, Efficacy and Suitability for Combination Therapy in HIV-Infected Patients
Jan 31, 2008
|
15.4 KB |
|
| |
NEW HAVEN, Conn., Jan 31, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced positive safety and efficacy results from two ongoing Phase 2 clinical trials studying elvucita...
|
|
Achillion Announces Appointment of New Chief Medical Officer
Nov 26, 2007
|
10.4 KB |
|
| |
NEW HAVEN, Conn., Nov 26, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the appointment of Dr. Elizabeth A. Olek as vice president and chief medical officer. Dr. Olek ...
|
|
Achillion to Present At Upcoming Conferences
Nov 2, 2007
|
9.1 KB |
|
| |
NEW HAVEN, Conn., Nov 2, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer of Achillion, will be presentin...
|
|
Achillion Reports Third Quarter 2007 Financial Results
Nov 2, 2007
|
13.6 KB |
|
| |
NEW HAVEN, Conn., Nov 2, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter ended September 30, 2007.
For the third quarter of 2007, th...
|
|
Achillion Reports Safety and Potent Antiviral Activity in Topline Results From Elvucitabine Phase 2 Study in HIV-Infected Patients
Oct 15, 2007
|
12.1 KB |
|
| |
NEW HAVEN, Conn., Oct 15, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced preliminary 12-week results from an ongoing Phase 2 clinical trial studying elvucitabine in pat...
|
|
|
= add release to Briefcase
|
